Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria.
- Corrado D Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy. Electronic address: domenico.corrado@unipd.it.
- Perazzolo Marra M Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- Zorzi A Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- Beffagna G Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- Cipriani A Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- Lazzari M Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- Migliore F Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- Pilichou K Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- Rampazzo A Department of Biology, University of Padova, Italy.
- Rigato I Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- Rizzo S Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- Thiene G Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- Anastasakis A Unit of Inherited and Rare Cardiovascular Diseases, Onassis Cardiac Surgery Centre, Leof. Andrea Siggrou 356, Kallithea 176 74, Greece.
- Asimaki A Molecular and Clinical Sciences Research Institute, St. George's University of London NHS Trust, Cranmer Terrace, London SW17 0RE, UK.
- Bucciarelli-Ducci C Department of Cardiology, Bristol Heart Institute, University Hospitals Bristol NHS Foundation, Trust Headquarters, Marlborough St, Bristol BS1 3NU, UK.
- Haugaa KH Department of Cardiology, Center for Cardiological Innovation, Oslo University Hospital, Rikshospitalet, Sognsvannsveien 20, 0372 Oslo, Norway.
- Marchlinski FE Cardiac Electrophysiology Program, Cardiovascular Division Hospital of the University of Pennsylvania, 9 Founders Pavilion - Cardiology, 3400 Spruce St, Philadelphia, PA 19104, USA.
- Mazzanti A Department of Molecular Medicine, University of Pavia, Corso Str. Nuova 25, Pavia, Italy.
- McKenna WJ Institute of Cardiovascular Science, University College London, London, UK.
- Pantazis A Inherited Cardiovascular Conditions services, The Royal Brompton and Harefield Hospitals, Sydney St, Chelsea, London SW3 6NP, UK.
- Pelliccia A Department of Cardiology, Institute of Sports Medicine and Science, Largo Piero Gabrielli, 1, 00197 Roma, Italy.
- Schmied C Department of Cardiology, University Heart Center Zurich, University Hospital Zurich, Ra ̈mistrasse 100, 8091 Zürich, Switzerland.
- Sharma S Cardiology Clinical Academic Group, St George's University of London, Cranmer Terrace, Tooting, London SW17 0RE, UK.
- Wichter T Heart Center Osnabrück, Bad Rothenfelde Niels-Stensen-Kliniken Marienhospital Osnabrück, Ulmenallee 5 - 11, 49214 Bad Rothenfelde, Germany.
- Bauce B Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- Basso C Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.
- 2020-06-21
Published in:
- International journal of cardiology. - 2020
English
The original designation of "Arrhythmogenic right ventricular (dysplasia/) cardiomyopathy"(ARVC) was used by the scientists who first discovered the disease, in the pre-genetic and pre-cardiac magnetic resonance era, to describe a new heart muscle disease predominantly affecting the right ventricle, whose cardinal clinical manifestation was the occurrence of malignant ventricular arrhythmias. Subsequently, autopsy investigations, genotype-phenotype correlations studies and the increasing use of contrast-enhancement cardiac magnetic resonance showed that the fibro-fatty replacement of the myocardium represents the distinctive phenotypic feature of the disease that affects the myocardium of both ventricles, with left ventricular involvement which may parallel or exceed the severity of right ventricular involvement. This has led to the new designation of "Arrhythmogenic Cardiomyopathy" (ACM), that represents the evolution of the original term of ARVC. The present International Expert Consensus document proposes an upgrade of the criteria for diagnosis of the entire spectrum of the phenotypic variants of ACM. The proposed "Padua criteria" derive from the diagnostic approach to ACM, which has been developed over 30 years by the multidisciplinary team of basic researchers and clinical cardiologists of the Medical School of the University of Padua. The Padua criteria are a working framework to improve the diagnosis of ACM by introducing new diagnostic criteria regarding tissue characterization findings by contrast-enhanced cardiac magnetic resonance, depolarization/repolarization ECG abnormalities and ventricular arrhythmia features for diagnosis of the left ventricular phenotype. The proposed diagnostic criteria need to be further validated by future clinical studies in large cohorts of patients.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1016/j.ijcard.2020.06.005
- PMID 32561223
- Persistent URL
- https://sonar.ch/global/documents/26845
Statistics
Document views: 101
File downloads:
- Full-text: 0